Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3333
Structure:
Synonyms:
(+)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
(+-)-Ethyl methyl
(+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
(+/-) ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
1A Brand of Felodipine
3,5-Pyridinedicarboxylic acid 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester (- );
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methyl ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester
3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester
3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (+-)-
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-,ethyl methyl ester, (+-)-
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester
72509-76-3
86189-69-7
AbZ Brand of Felodipine
AE-641/11429675
Agon
AGON SR
Aliud Brand of Felodipine
Alphapharm Brand of Felodipine
Alpharma Brand of Felodipine
Ambap1004
Astra Brand of Felodipine
AstraZeneca Brand of Felodipine
Aventis Brand of Felodipine
Azupharma Brand of Felodipine
BC Brand of Felodipine
betapharm Brand of Felodipine
BPBio1_000678
BRN 4331472
BSPBio_000616
C18H19Cl2NO4
CGH-869
CHEBI:585948
ct Arzneimittel Brand of Felodipine
ct-Arzneimittel Brand of Felodipine
D00319
D015736
DB01023
dl-Felodipine
ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
EU-0100508
F9677_SIGMA
Felo Biochemie
Felo Puren
Felo-Puren
Felobeta
Felocor
Feloday
Felodipin 1A Pharma
Felodipin AbZ
Felodipin AL
Felodipin AZU
Felodipin dura
Felodipin Heumann
Felodipin ratiopharm
Felodipin Stada
felodipin von ct
Felodipin-ratiopharm
Felodipina
Felodipina [INN-Spanish]
FELODIPINE
Felodipine (JAN/USP/INN)
Felodipine [INN:BAN]
Felodipine [USAN:BAN:INN]
Felodipine [USAN:INN:BAN]
Felodipinum
Felodipinum [INN-Latin]
Felodur
Felodur ER
Felogamma
Felogard
Fensel
Flodil
H 154 82
H 154-82
H 154/82
H 15482
H-154/82
Heumann Brand of Felodipine
Heumann, Felodipin
Hexal Brand of Felodipine
Hoechst Brand of Felodipine
Hydac
Lexxel
Logimax
Lopac0_000508
LS-131202
Merck dura Brand of Felodipine
Mixture Name
MLS000069629
MLS001077361
MLS001333735
MLS002153409
MLS002153832
Modip
Munobal
Munobal Retard
NCGC00093906-01
NCGC00093906-02
O3-ethyl O5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Penedil
Perfudal
Pharmaceutica Astra Brand of Felodipine
Pharmacia Spain Brand of Felodipine
Plendil
Plendil (TN)
Plendil Depottab
Plendil ER
Plendil Retard
Preslow
Prestwick0_000478
Prestwick1_000478
Prestwick2_000478
Prestwick3_000478
Prestwick_797
Prevex
Promed Brand of Felodipine
ratiopharm Brand of Felodipine
Renedil
SMR000058204
SPBio_002555
Splendil
Stadapharm Brand of Felodipine
TheraPharm Brand of Felodipine
W?rwag Brand of Felodipine
ATC-Codes:
Side-Effects:
Side-EffectFrequency
insomnia0.0010
tachycardia0.0010
syncope0.0010
sexual dysfunction0.0010
pruritis0.0010
polyuria0.0010
nervousness0.0010
myocardial infarction0.0010
muscle cramps0.0010
flu0.0010
tremor0.0010
urticaria0.0010
urinary frequency0.0010
bradycardia0.0010
photosensitivity0.0010
regurgitation0.0010
myalgia0.0010
leucocytoclastic vasculitis0.0010
urinary urgency0.0010
dry mouth0.0010
vomiting0.0010
impotence0.0010
postural hypotension0.0010
hypotension0.0010
confusion0.0010
chest pain0.0010
arthralgia0.0010
arrhythmia0.0010
anxiety0.0010
angioedema0.0010
angina pectoris0.0010
anemia0.0010
abdominal pain0.0010
diarrhea0.0010
somnolence0.0010
dyspnea0.0010
salivary gland enlargement0.0010
hepatitis0.0010
flatulence0.0010
fever0.0010
erythema nodosum0.0010
erythema multiforme0.0010
epistaxis0.0010
edema0.0010
dysuria0.0010
arm pain0
palpitations0
sneezing0
sinusitis0
peripheral edema0
bronchitis0
hip pain0
decreased libido0
nausea0
infection0
flushing0
headache0
irritability0
asthenia0
dyspepsia0
rhinorrhea0
rash0
foot pain0
back pain0
constipation0
paresthesia0
cough0
knee pain0
leg pain0
upper respiratory tract infection0
dizziness0
pharyngitis0
gynecomastia0
erythema0

Target

show target details
Uniprot ID:CP3A4_HUMAN
Synonyms:
Albendazole monooxygenase
Albendazole sulfoxidase
CYPIIIA3
CYPIIIA4
Cytochrome P450 3A3
Cytochrome P450 3A4
HLp
NF-25
Nifedipine oxidase
P450-PCN1
Quinine 3-monooxygenase
Taurochenodeoxycholate 6-alpha-hydroxylase
EC-Numbers:1.14.13.32
1.14.13.67
1.14.13.97
Organism:Homo sapiens
Human
PDB IDs:1TQN 1W0E 1W0F 1W0G 2J0D 2V0M
Structure:
2V0M

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----
----
----
----

References:

011861813
10640508
Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.. B Ma; T Prueksaritanont; J H Lin (2000) Drug metabolism and disposition: the biological fate of chemicals display abstract
The inhibitory effects of six commonly used calcium channel blockers on three major cytochrome P-450 activities were examined and characterized in human liver microsomes. All six compounds reversibly inhibited CYP2D6 (bufuralol 1'-hydroxylation) and CYP2C9 (tolbutamide methyl hydroxylation) activities. The IC(50) values for the inhibition of CYP2D6 and CYP2C9 for nicardipine were 3 to 9 microM, whereas those for all others ranged from 14 to >150 microM. Except for nifedipine, all calcium channel blockers showed increased inhibitory potency toward CYP3A activities (testosterone 6beta-hydroxylation and midazolam 1'-hydroxylation) after 30-min preincubation with NADPH. IC(50) values for the inhibition of testosterone 6beta-hydroxylase obtained in the NADPH-preincubation experiment for nicardipine (1 microM), verapamil (2 microM), and diltiazem (5 microM) were within 10-fold, whereas those for amlodipine (5 microM) and felodipine (13 microM) were >200-fold of their respective plasma concentrations reported after therapeutic doses. Similar results also were obtained based on midazolam 1'-hydroxylase activity. Unlike the observations with mibefradil, a potent irreversible inhibitor of CYP3A, the NADPH-dependent inhibition of CYP3A activity by nicardipine and verapamil was completely reversible on dialysis, whereas that by diltiazem was partially restored (80%). Additional experiments revealed that nicardipine, verapamil, and diltiazem formed cytochrome P-450-iron (II)-metabolite complex in both human liver microsomes and recombinant CYP3A4. Nicardipine yielded a higher extent of complex formation ( approximately 30% at 100 microM), and was a much faster-acting inhibitor (maximal inhibition rate constant approximately 2 min(-1)) as compared with verapamil and diltiazem. These present findings that the CYP3A inhibition caused by nicardipine, verapamil, and diltiazem is, at least in part, quasi-irreversible provide a rational basis for pharmacokinetically significant interactions reported when they were coadministered with agents that are cleared primarily by CYP3A-mediated pathways.
11963641
8554939
An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.. R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park (1995) British journal of clinical pharmacology display abstract
1. We have assessed the interaction of the antimalarial halofantrine with cytochrome P450 (CYP) enzymes in vitro, with the use of microsomes from human liver and recombinant cell lines. 2. Rac-halofantrine was a potent inhibitor (IC50 = 1.06 microM, Ki = 4.3 microM) of the 1-hydroxylation of bufuralol, a marker for CYP2D6 activity. Of a group of structurally related antimalarials tested, only quinidine (IC50 = 0.04 microM) was more potent. 3. Microsomes prepared from recombinant CYP2D6 and CYP3A4 cell lines were shown to catalyse halofantrine N-debutylation. 4. The metabolism of halofantrine to its N-desbutyl metabolite by human liver microsomes showed no correlation with CYP2D6 genotypic or phenotypic status and there was no consistent inhibition by quinidine. 5. The rate of halofantrine metabolism showed a significant correlation with both CYP3A4 protein levels (r = 0.88, P = 0.01) and the rate of felodipine metabolism (r = 0.86, P = 0.013), a marker substrate for CYP3A4 activity. Inhibition studies showed that ketoconazole is a potent inhibitor of halofantrine metabolism (IC50 = 1.57 microM). 6. In conclusion, we have demonstrated that halofantrine is a potent inhibitor of CYP2D6 in vitro and can also be metabolised by the enzyme. However, in human liver microsomes it appears to be metabolised largely by CYP3A4.
8554939
An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.. R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park (1995) British journal of clinical pharmacology display abstract
1. We have assessed the interaction of the antimalarial halofantrine with cytochrome P450 (CYP) enzymes in vitro, with the use of microsomes from human liver and recombinant cell lines. 2. Rac-halofantrine was a potent inhibitor (IC50 = 1.06 microM, Ki = 4.3 microM) of the 1-hydroxylation of bufuralol, a marker for CYP2D6 activity. Of a group of structurally related antimalarials tested, only quinidine (IC50 = 0.04 microM) was more potent. 3. Microsomes prepared from recombinant CYP2D6 and CYP3A4 cell lines were shown to catalyse halofantrine N-debutylation. 4. The metabolism of halofantrine to its N-desbutyl metabolite by human liver microsomes showed no correlation with CYP2D6 genotypic or phenotypic status and there was no consistent inhibition by quinidine. 5. The rate of halofantrine metabolism showed a significant correlation with both CYP3A4 protein levels (r = 0.88, P = 0.01) and the rate of felodipine metabolism (r = 0.86, P = 0.013), a marker substrate for CYP3A4 activity. Inhibition studies showed that ketoconazole is a potent inhibitor of halofantrine metabolism (IC50 = 1.57 microM). 6. In conclusion, we have demonstrated that halofantrine is a potent inhibitor of CYP2D6 in vitro and can also be metabolised by the enzyme. However, in human liver microsomes it appears to be metabolised largely by CYP3A4.
9153299
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.. K S Lown; D G Bailey; R J Fontana; S K Janardan; C H Adair; L A Fortlage; M B Brown; W Guo; P B Watkins (1997) The Journal of clinical investigation display abstract
The increase in oral availability of felodipine and other commonly used medications when taken with grapefruit juice has been assumed to be due to inhibition of CYP3A4, a cytochrome P450 that is present in liver and intestine. To evaluate the effect of repeated grapefruit juice ingestion on CYP3A4 expression, 10 healthy men were given 8 oz of grapefruit juice three times a day for 6 d. Before and after receiving grapefruit juice, small bowel and colon mucosal biopsies were obtained endoscopically, oral felodipine kinetics were determined, and liver CYP3A4 activity was measured with the [14C N-methyl] erythromycin breath test in each subject. Grapefruit juice did not alter liver CYP3A4 activity, colon levels of CYP3A5, or small bowel concentrations of P-glycoprotein, villin, CYP1A1, and CYP2D6. In contrast, the concentration of CYP3A4 in small bowel epithelia (enterocytes) fell 62% (P = 0.0006) with no corresponding change in CYP3A4 mRNA levels. In addition, enterocyte concentrations of CYP3A4 measured before grapefruit juice consumption correlated with the increase in Cmax when felodipine was taken with either the 1st or the 16th glass of grapefruit juice relative to water (r = 0. 67, P = 0.043, and r = 0.71, P = 0.022, respectively). We conclude that a mechanism for the effect of grapefruit juice on oral felodipine kinetics is its selective downregulation of CYP3A4 in the small intestine.